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Abstract 
It has been shown that stable transfection of insulin cDNA into the human liver cell 
line Huh7 resulted in synthesis, storage and regulated release of insulin to a glucose 
stimulus (Huh7ins cells). However, Huh7ins cells responded to glucose at sub-
physiological levels (2.5mM) and in order to maintain normoglycaemia, insulin 
secretion in response to physiological levels of glucose is required. Consequently, the 
Huh7ins cells were further transfected with the human glucokinase gene to correct the 
skewed insulin secretory profile. The resulting cell line (Melligen) responds to 
glucose in the 4-5mM physiological range.  
 
If Melligen cells are to be used clinically to correct patient blood glucose 
concentrations, they need to be resistant to the toxic effects of pro-inflammatory 
cytokines responsible for the immune-mediated destruction of beta cells. Pro-
inflammatory cytokines such as interferon-gamma (IFN-γ), tumour necrosis factor-
alpha (TNF-α) and interleukin-1 beta (IL-1β) play a major role in beta cell elimination 
during diabetes development. The aim of the present study was to determine if 
Melligen cells were resistant to the toxic effects of these cytokines.  
 
Cells were exposed to IFN-γ (384ng/mL), TNF-α (10ng/mL) and IL-1β (2ng/mL) for 
up to 10 days. Cell viability was measured using the Annexin V/propidium iodide 
(PI), PI and MTT cell viability assays. Insulin storage and chronic secretion were 
measured by radioimmunoassay. Acute insulin secretion was also determined by 
static incubations with increasing concentrations of 0, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5 and 
20mM glucose. Nitric oxide levels were assayed by the Griess reaction. The glucose-
responsive beta cell line, MIN-6, was used as a positive control throughout. 
Expression of the cytokine receptors IFNR1, IFNR2, IL1R1, IL1R2, TNFR1 and 
TNFR2 was determined in human pancreatic islet cells and the liver cell lines cultured 
in the absence of the cytokine treatment by RT-PCR. The quantitative analysis of the 
inhibitors of NF-κB (IκB-α, IκB-β IκB-ε) and NF-κB downstream effectors, iNOS, 
MCP-1 and Fas, was determined by real time RT-PCR in cytokine treated Huh7ins 
and Melligen cells with islet cells used as a positive control. Microarray analysis was 
used to determine which gene networks were being induced after 1h or 24h cytokine 
treatment of Melligen cells. Melligen cells were also tested for suitability for 
implantation. They were encapsulated (AustriaNova, Singapore) and insulin secretion 
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and glucose responsiveness were determined. The cells were also treated with a single 
or double dose of 100µM or 20mM STZ to determine susceptibility to this beta cell 
toxin. 
 
The viability of MIN-6 cells was reduced after 2 days of culture with cytokines (P< 
0.05). In contrast, the viability of Huh7, Huh7ins and Melligen cells was unaffected 
by cytokine treatment over 10 days. In addition to this, flow cytometry results 
corroborated the fact that there was no apoptotic cell death in these cell lines. The 
triple cytokines did not diminish chronic insulin secretion, storage or the glucose-
responsiveness of Melligen cells even after 10 days of co-culture. After exposure to 
cytokines MIN-6 cells also produced higher levels of nitric oxide as compared to 
Huh7ins cells (P<0.05). Expression of cytokine receptors IFNR1, IFNR2, IL1R1, 
IL1R2 and TNFR1 was detected in pancreatic islet cells and all liver cell lines. 
However, there was an absence of cytokine receptor TNFR2 expression in the liver 
cell lines. Real time RT-PCR results revealed down-regulation of the inhibitors of 
NF-κB and Fas in Huh7ins and Melligen cells, which is in contrast to the molecular 
mechanism seen in islet cells. The liver cell lines expressed very low levels of iNOS 
and there was no expression of MCP-1 detected by RT-PCR. Microarray analysis also 
revealed a network of genes up-regulated by NF-κB. Encapsulation of Melligen cells 
did not affect insulin function of the cells and the double dose 100µM STZ treatment 
did not affect the cells (P>0.05). 
 
In summary, Huh7ins and Melligen cells were more resistant to the toxic effects of 
pro-inflammatory cytokines as compared to pancreatic beta cells most likely by NF-
κB dependent pathways. These findings suggest that insulin-secreting hepatocytes 
will be less susceptible to destruction by the autoimmune process that eliminates beta 
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